HUP0301057A3 - Angiotenzin ii antagonist heterocyclic compound an their use for preparation of tnf-alpha inhibitors - Google Patents

Angiotenzin ii antagonist heterocyclic compound an their use for preparation of tnf-alpha inhibitors

Info

Publication number
HUP0301057A3
HUP0301057A3 HU0301057A HUP0301057A HUP0301057A3 HU P0301057 A3 HUP0301057 A3 HU P0301057A3 HU 0301057 A HU0301057 A HU 0301057A HU P0301057 A HUP0301057 A HU P0301057A HU P0301057 A3 HUP0301057 A3 HU P0301057A3
Authority
HU
Hungary
Prior art keywords
angiotenzin
tnf
antagonist
preparation
heterocyclic compound
Prior art date
Application number
HU0301057A
Other languages
English (en)
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of HUP0301057A2 publication Critical patent/HUP0301057A2/hu
Publication of HUP0301057A3 publication Critical patent/HUP0301057A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HU0301057A 2000-02-18 2001-02-15 Angiotenzin ii antagonist heterocyclic compound an their use for preparation of tnf-alpha inhibitors HUP0301057A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000046828 2000-02-18
PCT/JP2001/001069 WO2001060362A1 (en) 2000-02-18 2001-02-15 TNF-α INHIBITORS

Publications (2)

Publication Number Publication Date
HUP0301057A2 HUP0301057A2 (hu) 2003-12-29
HUP0301057A3 true HUP0301057A3 (en) 2004-01-28

Family

ID=18569174

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301057A HUP0301057A3 (en) 2000-02-18 2001-02-15 Angiotenzin ii antagonist heterocyclic compound an their use for preparation of tnf-alpha inhibitors

Country Status (10)

Country Link
US (1) US6833381B2 (hu)
EP (1) EP1262180A4 (hu)
KR (1) KR20030016229A (hu)
CN (1) CN1404390A (hu)
AU (2) AU3408801A (hu)
CA (1) CA2400124C (hu)
HU (1) HUP0301057A3 (hu)
NO (1) NO20023913L (hu)
PL (1) PL356422A1 (hu)
WO (1) WO2001060362A1 (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100224601B1 (ko) * 1997-05-13 1999-10-15 윤종용 복합기의 자동 급지장치
CA2426674A1 (en) * 2000-10-25 2002-05-02 Takeda Chemical Industries, Ltd. Agent for preventing or treating portal hypertension
US20040097565A1 (en) * 2001-01-29 2004-05-20 Terashita Zen-Ichi Analgesic and antiinflammatory drugs
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
MXPA03009622A (es) * 2001-04-23 2005-03-07 Amaxa Gmbh Solucion amortiguadora para electroporacion y metodo que comprende el uso de la misma.
CA2466659A1 (en) * 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Anticancer agents
CA2468827A1 (en) * 2001-12-03 2003-06-12 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
JP4484427B2 (ja) * 2001-12-03 2010-06-16 武田薬品工業株式会社 インスリン抵抗性改善剤
US7790681B2 (en) * 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US20040209803A1 (en) * 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
CA2511737A1 (en) * 2002-12-27 2004-07-22 Takeda Pharmaceutical Company Limited Body weight gain inhibitor
US20050201989A1 (en) * 2004-02-19 2005-09-15 St. Camillus Medical, Inc. Compositions and methods for ex vivo preservation of blood vessels for vascular grafts using inhibitors of tumor necrosis factor-alpha
WO2005105088A2 (en) * 2004-04-23 2005-11-10 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
JP4880591B2 (ja) 2004-06-04 2012-02-22 テバ ファーマシューティカル インダストリーズ リミティド イルベサルタンを含む医薬組成物
US20050288272A1 (en) * 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
US20070054948A1 (en) * 2004-09-02 2007-03-08 Lilach Hedvati Purification of olmesartan medoxomil
US20060074117A1 (en) * 2004-09-02 2006-04-06 Lilach Hedvati Purification of olmesartan medoxomil
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
ATE526963T1 (de) * 2006-05-04 2011-10-15 Lek Pharmaceuticals Pharmazeutische zusammensetzung mit olmesartan- medoxomil
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
CL2008000868A1 (es) * 2007-03-28 2008-10-10 Takeda Pharmaceutical Composicion farmaceutica solida que comprende un compuesto derivado de benzimidazol y un agente de control de ph; metodo de estabilizacion y de mejoramiento de la disolucion; uso de un agente de control de ph.
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
EP2321281A4 (en) 2008-09-02 2011-09-28 Elder Pharmaceuticals Ltd INFLAMMATORY CONNECTIONS
CN104428293B (zh) * 2012-06-11 2018-06-08 Ucb生物制药私人有限公司 调节TNFα的苯并咪唑类
GB201321733D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
GB201620948D0 (en) * 2016-12-09 2017-01-25 Ucb Biopharma Sprl Therapeutic agents
EP3615032A4 (en) * 2017-04-28 2020-12-23 Asana BioSciences, LLC FORMULATIONS, PROCEDURES, KITS AND DOSING FORMS FOR TREATMENT OF ATOPIC DERMATITIS AND IMPROVED STABILITY OF AN ACTIVE INGREDIENT

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5605919A (en) * 1993-02-26 1997-02-25 Takeda Chemical Industries, Ltd. Treatment for viral diseases
CA2115985A1 (en) * 1993-02-25 1994-08-26 Kohei Nishikawa Vascular hypertrophy suppressor
JP3810020B2 (ja) * 1993-04-22 2006-08-16 武田薬品工業株式会社 腎疾患の予防または治療剤
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
US5824696A (en) * 1993-09-01 1998-10-20 Smithkline Beecham Corporation Medicaments
CA2181461A1 (en) * 1994-02-08 1995-08-17 Alica Huxley Treatment of normotensive glaucoma with angiotensin ii antagonists
SE9501881D0 (sv) * 1995-05-19 1995-05-19 Astra Ab New pharmacological use of AII-receptor antagonists
EP0831911B1 (en) * 1995-06-07 2002-04-17 G.D. Searle & Co. Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure
CA2224451A1 (en) * 1995-06-30 1997-01-23 Merck & Co., Inc. Method of treating renal disease using an ace inhibitor and an aii antagonist
KR19990087076A (ko) 1996-04-05 1999-12-15 다께다 구니오 안지오텐신 ⅱ 및 길항 활성을 갖는 화합물을 함유하는 약제학적 배합물
IL130599A0 (en) * 1997-01-10 2000-06-01 Merck & Co Inc Use of angiotensin II antagonists to treat symptomatic heart failure
AU747110B2 (en) * 1998-02-25 2002-05-09 Merck & Co., Inc. Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist
BR9908474A (pt) * 1998-03-04 2000-12-05 Takeda Chemical Industries Ltd Preparação de liberação prolongada, processo para a produção de uma preparação de liberação prolongada, e, composição farmacêutica
JP2000159671A (ja) * 1998-12-01 2000-06-13 Takeda Chem Ind Ltd 血管新生阻害剤

Also Published As

Publication number Publication date
NO20023913L (no) 2002-09-10
AU2001234088B2 (en) 2005-12-01
US20030055039A1 (en) 2003-03-20
CA2400124A1 (en) 2001-08-23
CN1404390A (zh) 2003-03-19
PL356422A1 (en) 2004-06-28
NO20023913D0 (no) 2002-08-16
CA2400124C (en) 2010-12-14
WO2001060362A1 (en) 2001-08-23
US6833381B2 (en) 2004-12-21
AU3408801A (en) 2001-08-27
EP1262180A4 (en) 2005-06-01
HUP0301057A2 (hu) 2003-12-29
KR20030016229A (ko) 2003-02-26
EP1262180A1 (en) 2002-12-04

Similar Documents

Publication Publication Date Title
HUP0301057A3 (en) Angiotenzin ii antagonist heterocyclic compound an their use for preparation of tnf-alpha inhibitors
AU6116701A (en) Beta-carboline derivatives useful as inhibitors of phosphodiesterase
AU2003269850A8 (en) Hemisuccinate salts of heterocyclic dpp-iv inhibitors
AU2003251559A8 (en) Heterocyclic inhibitors of kinases
HK1105864A1 (en) Heterocyclic compounds which are active as inhibitors of beta-lactamases
EE200200140A (et) Pteridinoonid kui kinaasi inhibiitorid
EP1383506A4 (en) FUSED PHOSPHODIESTERASE (PDE) HETEROCYCLIC INHIBITORS 7
HUP0303868A3 (en) Substituted triazole diamine derivatives as kinase inhibitors and their use for preparation of pharmaceutical compositions
HK1054034B (zh) 用作磷酸二酯酶抑制劑的取代的吡咯並吡啶酮衍生物
EP1560582A4 (en) AZAINDOL DERIVATIVES AS INHIBITORS OF THE p38 KINASE
IL159926A0 (en) Aminoisoxazole derivatives active as kinase inhibitors
EE200100509A (et) Aminopürimidiinid kui sorbitooldehüdrogenaasi inhibiitorid
EE200300015A (et) Kolhinooli derivaadid kui angiogeneesi inhibiitorid
IL148719A0 (en) Kinase inhibitors as therapeutic agents
PL2384753T3 (pl) Pochodne hydantoiny jako inhibitory martwicy komórkowej
EP1165521A4 (en) FUSED COMPOUNDS OF PYRIDOPYRIDAZINE CGMP PHOSPHODIESTERASE INHIBITORS
NO20022125D0 (no) Pyrrolderivater som inhibitorer for fosfodiesterase VII
PL355022A1 (en) Imidazopyridine derivatives as phosphodiesterase vii inhibitors
AP2003002719A0 (en) Use of cox-2 inhibitors for preventing immunodeficiency
NO20022232D0 (no) Imidazolforbindelser for anvendelse som inhibitorer for fosfodiesterase VII
HK1077520A1 (zh) 用作p38促細胞分裂原活化蛋白激酶抑制劑的吲哚類衍生物
IL161165A0 (en) Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist
EE200300266A (et) Asendatud 8-arüülkinoliinid kui fosfodiesteraas-4inhibiitorid
IL150806A0 (en) Piperidine-and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
NO20022123D0 (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees